Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Robert, Caroline [VerfasserIn]   i
 Long, Georgina V. [VerfasserIn]   i
 Brady, Benjamin [VerfasserIn]   i
 Dutriaux, Caroline [VerfasserIn]   i
 Di Giacomo, Anna Maria [VerfasserIn]   i
 Mortier, Laurent [VerfasserIn]   i
 Rutkowski, Piotr [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
 McNeil, Catriona M. [VerfasserIn]   i
 Kalinka, Ewa Anna [VerfasserIn]   i
 Lebbé, Céleste [VerfasserIn]   i
 Charles, Julie [VerfasserIn]   i
 Hernberg, Micaela M. [VerfasserIn]   i
 Savage, Kerry J. [VerfasserIn]   i
 Chiarion-Sileni, Vanna [VerfasserIn]   i
 Mihalcioiu, Catalin [VerfasserIn]   i
 Mauch, Cornelia [VerfasserIn]   i
 Arance, Ana [VerfasserIn]   i
 Cognetti, Francesco [VerfasserIn]   i
 Ny, Lars [VerfasserIn]   i
 Schmidt, Henrik [VerfasserIn]   i
 Schadendorf, Dirk [VerfasserIn]   i
 Gogas, Helen [VerfasserIn]   i
 Zoco, Jesús [VerfasserIn]   i
 Re, Sandra [VerfasserIn]   i
 Ascierto, Paolo A. [VerfasserIn]   i
 Atkinson, Victoria [VerfasserIn]   i
Titel:Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma
Verf.angabe:Caroline Robert, MD, PhD; Georgina V. Long, PhD, MBBS; Benjamin Brady, MD; Caroline Dutriaux, MD, PhD; Anna Maria Di Giacomo, MD, PhD; Laurent Mortier, MD, PhD; Piotr Rutkowski, MD, PhD; Jessica C. Hassel, MD; Catriona M. McNeil, MD; Ewa Anna Kalinka, MD; Céleste Lebbé, MD; Julie Charles, MD, PhD; Micaela M. Hernberg, MD; Kerry J. Savage, MSc, MD; Vanna Chiarion-Sileni, MD; Catalin Mihalcioiu, MD; Cornelia Mauch, MD, PhD; Ana Arance, MD, PhD; Francesco Cognetti, MD; Lars Ny, MD; Henrik Schmidt, MD; Dirk Schadendorf, MD; Helen Gogas, MD, PhD; Jesús Zoco, MS; Sandra Re, MD,MB; Paolo A. Ascierto, MD; and Victoria Atkinson, MD
E-Jahr:2020
Jahr:September 30, 2020
Umfang:12 S.
Fussnoten:Gesehen am 29.01.2021
Titel Quelle:Enthalten in: Journal of clinical oncology
Ort Quelle:Alexandria, Va. : American Society of Clinical Oncology, 1983
Jahr Quelle:2020
Band/Heft Quelle:38(2020), 33, Seite 3937-3946
ISSN Quelle:1527-7755
Abstract:PURPOSEThe CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.PATIENTS AND METHODSIn this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m2 every 3 weeks. The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.RESULTSPatients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine). Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively. Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37). ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively. Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis. Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free. Safety analyses were similar to the 3-year report.CONCLUSIONResults from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy. Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies.
DOI:doi:10.1200/JCO.20.00995
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1200/JCO.20.00995
 Volltext: https://ascopubs.org/doi/10.1200/JCO.20.00995
 DOI: https://doi.org/10.1200/JCO.20.00995
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1745984518
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68685886   QR-Code
zum Seitenanfang